Clinical Trial

Effects of Ublituximab on Motor Functions in Multiple Sclerosis

Study acronym: U-PACE
Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated February 9, 2026 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to test if ublituximab changes walking functions and fall risk in people with relapsing multiple sclerosis (RMS). Twenty-five qualified people with RMS will undergo a 48-week ublituximab treatment. Before, 24 weeks into, and after the treatment, their ambulatory function, disability status, and cognition will be assessed. Additionally, they will experience large-scale slip perturbations on a treadmill under the protection of a safety harness at the last assessment. The outcome measures will be compared across the assessments to examine the effects of ublituximab on improving their walking function, disability status, cognition, and the responses to the unexpected slip perturbation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-03.
Status change: Not Yet Recruiting → Recruiting 2026-02-05
Trial Details
NCT Number NCT06629428
Lead Sponsor Georgia State University
Collaborators: Atlanta Neuroscience Institute
Conditions Multiple Sclerosis (MS) - Relapsing-remitting
Enrollment 25 participants
Start Date 2025-11-13
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-09